Biomarkers are so important because they allow us to pinpoint the unique causes of each person’s Alzheimer’s, which will make it possible to tailor treatments specifically for every patient in a precision medicine approach – the same approach that has proven successful in cancer treatment. Dr. Danielle Graham, Head of Biomarkers and System Biology at Biogen, develops novel biomarkers that allow her team to make sure they are enrolling the right patients in clinical trials and to track the effects of the drugs they are testing, making trials more efficient and getting drugs to patients faster.
“Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s disease. Now in its fifth season, this lecture series invites three top investigators to share the latest breaking updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the development of novel therapeutics and biomarkers to prevent, treat, and cure Alzheimer’s disease and related dementias.
Presented by the Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
